Your browser doesn't support javascript.
loading
Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.
Kvitne, Kine Eide; Krogstad, Veronica; Wegler, Christine; Johnson, Line Kristin; Kringen, Marianne K; Hovd, Markus Herberg; Hertel, Jens K; Heijer, Maria; Sandbu, Rune; Skovlund, Eva; Artursson, Per; Karlsson, Cecilia; Andersson, Shalini; Andersson, Tommy B; Hjelmesaeth, Jøran; Åsberg, Anders; Jansson-Löfmark, Rasmus; Christensen, Hege; Robertsen, Ida.
Afiliación
  • Kvitne KE; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Krogstad V; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Wegler C; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Johnson LK; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Kringen MK; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.
  • Hovd MH; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
  • Hertel JK; Department of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
  • Heijer M; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Sandbu R; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.
  • Skovlund E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Artursson P; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.
  • Karlsson C; Department of Surgery, Vestfold Hospital Trust, Tønsberg, Norway.
  • Andersson S; Department of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
  • Andersson TB; Department of Pharmacy and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Hjelmesaeth J; Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Åsberg A; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Jansson-Löfmark R; Research and Early Development, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Christensen H; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Robertsen I; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.
Br J Clin Pharmacol ; 88(9): 4121-4133, 2022 09.
Article en En | MEDLINE | ID: mdl-35404513
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Derivación Gástrica Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Noruega
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Derivación Gástrica Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Noruega